Anzeige
Meldung des Tages: Erste Genehmigung für Tiefseebergbau seit 1980: Warum dieser Meilenstein für den nächsten Small-Cap-Akteur wichtig ist

TransCode Therapeutics News

Aktie
WKN:  A4170U ISIN:  US89357L5012 US-Symbol:  RNAZ Branche:  Biotechnologie Land:  USA
8,06 $
+0,05 $
+0,62%
6,8766 € 01.05.26
Depot/Watchlist
Marktkapitalisierung *
4,98 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

TransCode Therapeutics News

27.04.26 - PR Newswire
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University PR Newswire
07.04.26 - PR Newswire
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 PR Newswire
03.03.26 - PR Newswire
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-​Free License to Develop and Commercialize a Next-​Generation Oncolytic Immunotherapy Platform in an All-Stock ...
23.02.26 - PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development PR Newswire
05.02.26 - PR Newswire
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 PR Newswire
06.01.26 - PR Newswire
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma PR Newswire
22.12.25 - PR Newswire
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors PR Newswire
11.12.25 - PR Newswire
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-​expansion trial with TTX-MC138, following positive readouts from TransCode's ...
17.11.25 - PR Newswire
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer PR Newswire
14.10.25 - PR Newswire
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO PR Newswire
08.10.25 - PR Newswire
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-​in-class unique ...
28.05.25 - PR Newswire
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »